AKBA
Akebia Therapeutics, Inc.
$1.40
-0.03 (-2.10%)
At close · Jul 10
Market Cap
$375.56M
Shares
268,258,243
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.40
Open$1.43
Day$1.36–1.44
52W$0.82–4.08
Avg vol 30d5.7M
Short int19.2M · 7.1% float · 2.7d
Short vol54%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 8, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
+25%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+60%
trailing
6-month return
+4%
trailing
YTD return
−13%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
4 of 171 funds reported for Jun 30 · net +6.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.15% of float · ▼ -34.3% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
171 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+94%
Y/Y
Free cash flow
$67.7M
Balance sheet
$136.6M
net cash
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
+25%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
4 of 171 funds reported for Jun 30 · net +6.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.15% of float · ▼ -34.3% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
171 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 18%
52-wk high $4
vs 200-day avg -12%
vs 50-day avg +25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients from dialysis organizations other than U.S. Renal Care | 20% | Q1 2026 | — |
| Prescriber growth | 28% | Q1 2026 | — |
| Prescribers from dialysis organizations other than U.S. Renal Care | 30% | Q1 2026 | — |
| Total number of prescribers | 1,025 | Q1 2026 | — |
|
|
|||
| patients on Vafseo | 7,500 | end of Q1 2026 call | — |
| patients with prescribing access | 290,000 | end of 2025 call | — |
| prescribers from dialysis organizations other than USRC | 30% | Q1 2026 call | — |
| prescribers writing prescriptions for Vafseo | 1,025 | Q1 2026 call | — |
| refill adherence rate for patients treated under observed dosing protocol | 86% | through the end of March 2026 call | — |
| First refill adherence rates (in-center observed dosing protocol centers) | 91% | Q4 2025 | — |
| Patient access to Vafseo therapy | 290,000 | Q4 2025 | — |
| Patient demand | $11M | Q4 2025 | — |
| First refill adherence rate at USRC centers (9 months 2025) | 75% | first 9 months of 2025 | — |
| First refill adherence rate at USRC centers (Q4 2025) | 91% | Q4 2025 | — |
| Q4 prescribers of Vafseo | 785 | Q4 2025 | — |
| Q4 Vafseo prescribers growth over Q3 | 8% | Q4 2025 | — |
| Vafseo prescribing access (patients on dialysis) | 275,000 | 2026 outlook | — |
| VOCAL Phase IV trial enrollment | 350 | 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKBA
this stock
Akebia Therapeutics, Inc.
|
$375.56M | -13.0% | +47.5% | — | 7.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.88B | +6.2% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.15B | +3.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.98B | -3.5% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKBA | +12.9% | +60.4% | +4.5% | +22.8% | -13.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +11.5% | +56.3% | -4.6% | +21.7% | -23.8% |